Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial

详细信息    查看全文

• 作者：Prof Nadia Harbeck ; MD^a ; Prof Chiun-Sheng Huang ; MD^b ; ^c ; Sara Hurvitz ; MD^d ; ^e ; Dah-Cherng Yeh ; MD^c ; ^f ; Prof Zhimin Shao ; MD^g ; Prof Seock-Ah Im ; MD^h ; Prof Kyung Hae Jung ; MDⁱ ; Kunwei Shen ; MD^j ; Jungsil Ro ; MD^k ; Prof Jacek Jassem ; MD^l ; Prof Qingyuan Zhang ; MD^m ; Young-Hyuck Im ; MDⁿ ; Prof Marek Wojtukiewicz ; MD^o ; Qiang Sun ; MD^p ; Prof Shin-Cheh Chen ; MD^c ; ^q ; Rainer-Georg Goeldner ; PhD^r ; Martina Uttenreuther-Fischer ; MD^r ; Prof Binghe Xu ; MD^s ; ^t ; ^{bhxu@hotmail.com" class="auth_mail" title="E-mail the corresponding author} ; Martine Piccart-Gebhart ; MD^u ; on behalf of the LUX-Breast 1 study group
• 刊名：The Lancet Oncology
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：17
• 期：3
• 页码：357-366
• 全文大小：574 K

文摘

Trastuzumab resistance is a key therapeutic challenge in metastatic breast cancer. We postulated that broader inhibition of ErbB receptors with afatinib would improve clinical outcomes compared with HER2 inhibition alone in patients who had progressed on previous trastuzumab treatment. LUX-Breast 1 compared afatinib plus vinorelbine with trastuzumab plus vinorelbine for such patients with HER2-positive metastatic breast cancer.

Methods

We did this open-label trial at 350 hospitals in 41 countries worldwide. We enrolled female patients with HER2-overexpressing metastatic breast cancer who had progressed on or following adjuvant trastuzumab or first-line treatment of metastatic disease with trastuzumab. Participants were randomly assigned (2:1) to receive oral afatinib (40 mg/day) plus intravenous vinorelbine (25 mg/m² per week) or intravenous trastuzumab (2 mg/kg per week after 4 mg/kg loading dose) plus vinorelbine. Randomisation was done centrally and stratified by previous trastuzumab treatment (adjuvant vs first-line treatment), hormone receptor status (oestrogen receptor and progesterone receptor positive vs others), and region. The primary endpoint was progression-free survival, assessed in the intention-to-treat population. This trial is closed to enrolment and is registered with ClinicalTrials.gov, NCT01125566.

Findings

Between Aug 26, 2010, and April 26, 2013, we enrolled 508 patients: 339 assigned to the afatinib group and 169 assigned to the trastuzumab group. Recruitment was stopped on April 26, 2013, after a benefit–risk assessment by the independent data monitoring committee was unfavourable for the afatinib group. Patients on afatinib plus vinorelbine had to switch to trastuzumab plus vinorelbine, afatinib monotherapy, vinorelbine monotherapy, or receive treatment outside of the trial. Median follow-up was 9·3 months (IQR 3·7–16·0). Median progression-free survival was 5·5 months (95% CI 5·4–5·6) in the afatinib group and 5·6 months (5·3–7·3) in the trastuzumab group (hazard ratio 1·10 95% CI 0·86–1·41; p=0·43). The most common drug-related adverse events of grade 3 or higher were neutropenia (190 [56%] of 337 patients in the afatinib group vs 102 [60%] of 169 patients in the trastuzumab group), leucopenia (64 [19%] vs 34 [20%]), and diarrhoea (60 [18%] vs none).

Interpretation

Trastuzumab-based therapy remains the treatment of choice for patients with HER2-positive metastatic breast cancer who had progressed on trastuzumab.

Funding

Boehringer Ingelheim.